Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1971 2
1972 8
1973 9
1974 9
1975 20
1976 11
1977 10
1978 13
1979 14
1980 14
1981 13
1982 22
1983 8
1984 24
1985 22
1986 14
1987 22
1988 21
1989 26
1990 31
1991 20
1992 23
1993 14
1994 22
1995 28
1996 20
1997 31
1998 25
1999 22
2000 18
2001 19
2002 22
2003 22
2004 30
2005 25
2006 24
2007 32
2008 38
2009 52
2010 63
2011 74
2012 119
2013 166
2014 204
2015 255
2016 265
2017 303
2018 329
2019 428
2020 555
2021 602
2022 624
2023 707
2024 727
2025 810
2026 548

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,628 results

Results by year

Filters applied: . Clear all
Page 1
Ketamine: Mechanisms and Relevance to Treatment of Depression.
Kim JW, Suzuki K, Kavalali ET, Monteggia LM. Kim JW, et al. Annu Rev Med. 2024 Jan 29;75:129-143. doi: 10.1146/annurev-med-051322-120608. Epub 2023 Sep 20. Annu Rev Med. 2024. PMID: 37729028 Free article. Review.
Major depressive disorder (MDD) is a leading cause of suicide in the world. Monoamine-based antidepressant drugs are a primary line of treatment for this mental disorder, although the delayed response and incomplete efficacy in some patients highlight the nee …
Major depressive disorder (MDD) is a leading cause of suicide in the world. Monoamine-based antidepressant drugs are a primary …
Ketamine for depression.
Jelen LA, Stone JM. Jelen LA, et al. Int Rev Psychiatry. 2021 May;33(3):207-228. doi: 10.1080/09540261.2020.1854194. Epub 2021 Feb 11. Int Rev Psychiatry. 2021. PMID: 33569971 Review.
Ketamine is a racemic mixture composed of equal amounts of (S)-ketamine and (R)-ketamine. Although ketamine currently remains an off-label treatment for TRD, an (S)-ketamine nasal spray has been approved for use in TRD (in conjunct …
Ketamine is a racemic mixture composed of equal amounts of (S)-ketamine and (R)-ketamine. Although ketamine …
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.
McIntyre RS, Rosenblat JD, Nemeroff CB, Sanacora G, Murrough JW, Berk M, Brietzke E, Dodd S, Gorwood P, Ho R, Iosifescu DV, Lopez Jaramillo C, Kasper S, Kratiuk K, Lee JG, Lee Y, Lui LMW, Mansur RB, Papakostas GI, Subramaniapillai M, Thase M, Vieta E, Young AH, Zarate CA Jr, Stahl S. McIntyre RS, et al. Am J Psychiatry. 2021 May 1;178(5):383-399. doi: 10.1176/appi.ajp.2020.20081251. Epub 2021 Mar 17. Am J Psychiatry. 2021. PMID: 33726522 Free PMC article. Review.
Ketamine and esketamine represent pharmacologically novel treatment avenues for adults with treatment-resistant depression. In addition to providing hope to affected persons, these agents represent the first non-monoaminergic agents with proven rapid-onset ef …
Ketamine and esketamine represent pharmacologically novel treatment avenues for adults with treatment-resistant depression …
Long-term safety of ketamine and esketamine in treatment of depression.
Nikayin S, Murphy E, Krystal JH, Wilkinson ST. Nikayin S, et al. Expert Opin Drug Saf. 2022 Jun;21(6):777-787. doi: 10.1080/14740338.2022.2066651. Epub 2022 Apr 19. Expert Opin Drug Saf. 2022. PMID: 35416105 Review.
INTRODUCTION: Ketamine can produce rapid-acting antidepressant effects. Esketamine (Spravato), the S-enantiomer of racemic ketamine, was approved by the FDA for treatment-resistant depression in 2019. ...However, severe bladder pathology has not been r …
INTRODUCTION: Ketamine can produce rapid-acting antidepressant effects. Esketamine (Spravato), the S-enantiomer of racemic …
Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability.
Smith-Apeldoorn SY, Veraart JK, Spijker J, Kamphuis J, Schoevers RA. Smith-Apeldoorn SY, et al. Lancet Psychiatry. 2022 Nov;9(11):907-921. doi: 10.1016/S2215-0366(22)00317-0. Lancet Psychiatry. 2022. PMID: 36244360
Ketamine has rapid yet often transient antidepressant effects in patients with treatment-resistant depression. Different strategies have been proposed to prolong these effects. Maintenance ketamine treatment appears promising, but little is known about its ef …
Ketamine has rapid yet often transient antidepressant effects in patients with treatment-resistant depression. Different strat …
Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis.
Alnefeesi Y, Chen-Li D, Krane E, Jawad MY, Rodrigues NB, Ceban F, Di Vincenzo JD, Meshkat S, Ho RCM, Gill H, Teopiz KM, Cao B, Lee Y, McIntyre RS, Rosenblat JD. Alnefeesi Y, et al. J Psychiatr Res. 2022 Jul;151:693-709. doi: 10.1016/j.jpsychires.2022.04.037. Epub 2022 May 25. J Psychiatr Res. 2022. PMID: 35688035
Ketamine is a promising therapeutic option in treatment-resistant depression (TRD). The acute efficacy of ketamine in TRD has been demonstrated in replicated randomised-controlled trials (RCTs), but the generalizability of RCT data to real-world practice is l …
Ketamine is a promising therapeutic option in treatment-resistant depression (TRD). The acute efficacy of ketamine in T …
Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis.
Bahji A, Vazquez GH, Zarate CA Jr. Bahji A, et al. J Affect Disord. 2021 Jan 1;278:542-555. doi: 10.1016/j.jad.2020.09.071. Epub 2020 Sep 23. J Affect Disord. 2021. PMID: 33022440 Free PMC article.
BACKGROUND: Ketamine appears to have a therapeutic role in certain mental disorders, most notably depression. ...RR = 1.47), as well as lower dropouts (RR = 0.76 vs. RR = 1.37). CONCLUSIONS: Intravenous ketamine appears to be more efficacious than intranasal …
BACKGROUND: Ketamine appears to have a therapeutic role in certain mental disorders, most notably depression. ...RR = 1.47), a …
Oral ketamine for depression: An updated systematic review.
Meshkat S, Haikazian S, Di Vincenzo JD, Fancy F, Johnson D, Chen-Li D, McIntyre RS, Mansur R, Rosenblat JD. Meshkat S, et al. World J Biol Psychiatry. 2023 Sep-Oct;24(7):545-557. doi: 10.1080/15622975.2023.2169349. Epub 2023 Jan 31. World J Biol Psychiatry. 2023. PMID: 36651238
Objectives: Ketamine is a glutamate N-methyl-D-aspartate receptor antagonist that can be used to treat major depressive disorder by single or repeated infusions. However, the accessibility and scalability of oral ketamine make it preferred over intrave …
Objectives: Ketamine is a glutamate N-methyl-D-aspartate receptor antagonist that can be used to treat major depressive dis …
Personalized use of ketamine and esketamine for treatment-resistant depression.
Medeiros GC, Demo I, Goes FS, Zarate CA Jr, Gould TD. Medeiros GC, et al. Transl Psychiatry. 2024 Nov 29;14(1):481. doi: 10.1038/s41398-024-03180-8. Transl Psychiatry. 2024. PMID: 39613748 Free PMC article. Review.
A large and disproportionate portion of the burden associated with major depressive disorder (MDD) is due to treatment-resistant depression (TRD). Intravenous (R,S)-ketamine (ketamine) and intranasal (S)-ketamine (esketam …
A large and disproportionate portion of the burden associated with major depressive disorder (MDD) is due to treatment-resista …
Pharmacotherapy: Ketamine and Esketamine.
Feeney A, Papakostas GI. Feeney A, et al. Psychiatr Clin North Am. 2023 Jun;46(2):277-290. doi: 10.1016/j.psc.2023.02.003. Epub 2023 Mar 10. Psychiatr Clin North Am. 2023. PMID: 37149345 Review.
Ketamine and esketamine have rapid-onset antidepressant effects and may be considered for the management of treatment-resistant depression. ...The long-term safety and efficacy of ketamine/esketamine as antidepressants require further study....
Ketamine and esketamine have rapid-onset antidepressant effects and may be considered for the management of treatment-resistan …
6,628 results